Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.

Purpose DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus. Preclinical studies demonstrated antiglioma efficacy, but the effects and mechanisms of action have not been evaluated in patients. Methods A phase I, dose-escalation, biologic-end-point clinical trial of DNX-2401 was conducted in 37 patients with recurrent malignant glioma. Patients received a single intratumoral injection of DNX-2401 into biopsy-confirmed recurrent tumor to evaluate safety and response across eight dose levels (group A). To investigate the mechanism of action, a second group of patients (group B) underwent intratumoral injection through a permanently implanted catheter, followed 14 days later by en bloc resection to acquire post-treatment specimens. Results In group A (n = 25), 20% of patients survived > 3 years from treatment, and three patients had a ≥ 95% reduction in the enhancing tumor (12%), with all three of these dramatic responses resulting in > 3 years of progression-free survival from the time of treatment. Analyses of post-treatment surgical specimens (group B, n = 12) showed that DNX-2401 replicates and spreads within the tumor, documenting direct virus-induced oncolysis in patients. In addition to radiographic signs of inflammation, histopathologic examination of immune markers in post-treatment specimens showed tumor infiltration by CD8+ and T-bet+ cells, and transmembrane immunoglobulin mucin-3 downregulation after treatment. Analyses of patient-derived cell lines for damage-associated molecular patterns revealed induction of immunogenic cell death in tumor cells after DNX-2401 administration. Conclusion Treatment with DNX-2401 resulted in dramatic responses with long-term survival in recurrent high-grade gliomas that are probably due to direct oncolytic effects of the virus followed by elicitation of an immune-mediated antiglioma response.

[1]  Jaime Rodriguez-Canales,et al.  Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients , 2016, Clinical Cancer Research.

[2]  F. Lang,et al.  Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. , 2015, Current opinion in virology.

[3]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[4]  A. Fleisher,et al.  In vivo performance of a microfabricated catheter for intraparenchymal delivery , 2014, Journal of Neuroscience Methods.

[5]  A. Kleijn,et al.  The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity , 2014, PloS one.

[6]  W. Yung,et al.  Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model , 2014, PloS one.

[7]  A. Anderson.  Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape , 2014, Cancer Immunology Research.

[8]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[9]  A. Friedman,et al.  Convection enhanced delivery of macromolecules for brain tumors. , 2012, Current drug discovery technologies.

[10]  Abhishek D. Garg,et al.  Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.

[11]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[12]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[13]  W. Olbricht,et al.  Microfluidic probes in the treatment of brain-related diseases. , 2010, Drug news & perspectives.

[14]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[15]  Sylvia Janetzki,et al.  Improved Endpoints for Cancer Immunotherapy Trials , 2010, Journal of the National Cancer Institute.

[16]  G. Freeman,et al.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection , 2010, Proceedings of the National Academy of Sciences.

[17]  Raghu Raghavan,et al.  Poor drug distribution as a possible explanation for the results of the PRECISE trial. , 2010, Journal of neurosurgery.

[18]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[19]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[20]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[21]  H. Colman,et al.  Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. , 2007, Journal of the National Cancer Institute.

[22]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[23]  A. Heim,et al.  Rapid and quantitative detection of human adenovirus DNA by real‐time PCR , 2003, Journal of medical virology.

[24]  G. Fuller,et al.  Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. , 2003, Journal of the National Cancer Institute.

[25]  P. Black,et al.  αvβ3 and αvβ5 Integrin Expression in Glioma Periphery , 2001 .

[26]  D. Kirn.  Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer , 2000, Oncogene.

[27]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[28]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Black,et al.  Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. , 2001, Neurosurgery.